SKIP28 Antibody
Description
SKIP Antibodies: General Overview
SKIP antibodies target the PLEKHM2 protein (Pleckstrin homology domain-containing protein family M2), which plays roles in Golgi organization, lysosome function, and cytoplasmic processes. These antibodies are used for detecting SKIP in biological samples via techniques like Western blot, ELISA, and immunofluorescence .
Role in Meiosis and DNA Repair
-
SKP1 (a component of SCF E3 ligase) regulates meiotic DNA double-strand breaks (DSBs) by targeting HORMAD1 for degradation. Loss of SKP1 disrupts chromosomal synapsis and cohesion during meiosis .
-
Mechanism: FBXO47 (an F-box protein) interacts with SKP1 to ubiquitinate HORMAD1, preventing pre-DSB complex accumulation .
Interaction with Muscle-Regulation Pathways
-
SKIP interacts with poly(A)-binding protein 2 (PABP2) to enhance muscle regulator expression, including MyoD and BetaM .
-
ChIP Assays: SKIP antibodies are used to study chromatin interactions in muscle cells, particularly at regulatory regions like DRR2 and CE .
Single-Domain Antibody (sdAb) Applications
While not specific to SKIP28, sdAbs like 2D8 (targeting α-synuclein) demonstrate high stability and therapeutic potential. These fragments are engineered for improved brain penetration and proteasomal degradation of target proteins .
Potential Confusion or Misidentification
The term "SKIP28" may refer to:
-
A Clone/Tag Number: Some commercial antibodies use alphanumeric identifiers (e.g., "2D8" in sdAb studies ). Search results list 98 SKIP antibodies , but none explicitly named "SKIP28".
-
A Synonym or Misannotation: SKIP is often conflated with SKP1 (a SCF ligase subunit) or PLEKHM2. Ensure terminology aligns with the target protein.
Recommendations for Further Investigation
-
Verify Nomenclature: Confirm if "SKIP28" refers to a specific clone, product code, or mistyped term (e.g., "SKP1").
-
Explore sdAb Platforms: Consider single-domain antibodies (e.g., 2D8 ) for enhanced stability and tissue penetration.
-
Review Commercial Catalogs: Biocompare lists 98 SKIP antibodies ; filter by reactivity, application, or supplier to identify candidates.
Data Tables: SKIP Antibody Applications and Performance
| Supplier | Product Code | Reactivity | Applications |
|---|---|---|---|
| Supplier A | AB123 | Hu, Ms, Rt | WB, ICC |
| Supplier B | AB456 | Hu | IF, ELISA |
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
Based on the available literature about E3 ubiquitin ligase systems and antibody applications in proteostasis research, here is a structured FAQ collection addressing key methodological challenges in studying SCF-class E3 ligase components (including potential SKIP28-related mechanisms):
What experimental designs resolve contradictions in substrate identification studies?
Conflicting reports about E3 ligase targets often arise from:
-
Context-dependent regulation: Wts phosphorylation stabilizes Ex by blocking Slmb binding
-
Technique limitations: BioID vs traditional IP-MS (β-TrCP1/2 substrate profiles differed by method )
Recommended workflow:
-
Orthogonal validation: Combine BioID proximity labeling with ubiquitination assays (e.g., HA-Ub pull-downs )
-
Conditional modulation: Test substrate stability under:
-
Structural mapping: Identify critical binding regions (e.g., Ex C2 domain requirement )
How to distinguish direct ubiquitination from bystander effects in E3 ligase studies?
Methodological solutions include:
-
In vitro reconstitution: Purified SCF components + candidate substrate (e.g., Cullin3-KLHL22/DEPDC5 system )
-
Time-resolved assays: Measure degradation kinetics using cycloheximide chase (Ex half-life analysis )
-
Ubiquitin linkage profiling: Use K48 vs K63 chain-specific antibodies
What strategies optimize PROTAC-antibody complexes for targeted protein degradation?
Advanced approaches from PROTAC research :
-
Non-covalent complexation: PROxAb Shuttle technology achieves 1.9:1 PROTAC:antibody ratio via VHH domains
-
Internalization monitoring: pH-responsive dye conjugates (VH032-pHAb )
-
Dual validation:
How to interpret conflicting ubiquitome vs proteome data in E3 ligase studies?
Case example: AMPKα regulation shows both K48 (proteasomal) and K63 (non-degradative) ubiquitination
Resolution framework:
-
Functional clustering:
-
Pathway crosstalk analysis: Hippo signaling suppresses both Ex transcription and Slmb-mediated degradation
What are the limitations of current E3 ligase activity assays?
Identified technical gaps:
